Insights
Media Center
Latest Therapy Updates
- Clinical Development Begins for Subcutaneous Cadonilimab, Advancing the Immuno-Oncology 2.0 Regimen
- Sichuan Kelun Pharmaceutical Co., Ltd. announced that its subsidiary’s core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) has been approved by the National Medical Products Administration for the fourth indication (for the treatment of 2L+ HR+/HER2- breast cancer).
- “Perfect ending” – the Proton Therapy Center of Sichuan Cancer Hospital successfully completed proton clinical research
- Jiefang Daily · Shangguan News: A First in China—Fudan and Huashan Explore an Ultrasound Brain–Computer Interface to Open the Blood–Brain Barrier in Three Minutes for Glioma Drug Delivery
- The trend of medical tourism has changed! Coming to China for medical treatment has become a new option as the industry prepares for Southeast Asia
Page 7 of 12
What could this mean for your care?
A promising treatment raises a personal question: could it be an option for you? Chirona helps you explore that question with the right specialists.
Start a case reviewHow our service worksUnderstand your options
Explore the treatments relevant to your diagnosis, previous care and priorities.
Bring your case to specialists
We help organise your medical records and coordinate a professional assessment of suitability and access.
Plan the next step together
If a treatment path is appropriate, we help coordinate consultations, hospital arrangements and continuity of care.